NICE recommends ‘breakthrough’ therapy for blood cancer Belantamab mafodotin combination therapy is a second-line treatment option for multiple myeloma that could benefit around 1,500 people.…
NICE recommends mirikizumab as a treatment option for Crohn’s disease Mirikizumab (Omvoh; Eli Lilly), which is already licensed to treat ulcerative colitis but at a lower dose, is now recommended for the treatment of moderately to severely active Crohn's disease.…
Chronic heart failure deaths could fall by 3,000 per year following updated guidance, says NICE The National Institute for Health and Care Excellence said that drugs are being introduced earlier in patient treatment for chronic heart failure, which has been reflected in its draft guidance.…
Why I set up a pharmacist-led one-stop diabetes clinic in my GP practice How the introduction of a pharmacist-led diabetes clinic has helped to free up GP time and reduce overall hospital admissions, while educating patients on essential care processes.…
NHS England looks to tender contract for behavioural support for patients prescribed tirzepatide in primary care The NHS England document said that patients prescribed tirzepatide in primary care settings will receive “high-quality behavioural wrap-around care” as well as clinical support.…
NICE to work with NHS Race and Health Observatory to de-bias clinical guidance The two-year partnership will examine clinical guidance across maternal and neonatal health, mental health, genomics, sickle cell and hypertension.…
NICE reverses draft guidance to recommend targeted therapy for patients with advanced bowel cancer The National Institute for Health and Care Excellence said the treatment should be available on the NHS after the manufacturer provided additional clinical evidence.…
NICE recommends cladribine for treating active relapsing forms of multiple sclerosis Cladribine (Mavenclad; Merck) is recommended for treating active relapsing-remitting multiple sclerosis in adults when high-efficacy disease-modifying therapies would be offered.…
NICE recommends capivasertib for advanced breast cancer Clinical trial results revealed that capivasertib, taken with fulvestrant, can provide advanced breast cancer patients with an additional four months before their cancer progresses.…
First UK joint asthma guidance: what does it mean for practice? In this episode of The PJ Pod, we explore the main changes and implications for practice brought about by the UK-wide joint asthma guideline.…
